Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453561 | 0.87 | POLB (0.59) | POLBKMT2AALDH1A1CA4CA1 | |
| SCHEMBL12710955 | 0.85 | POLB (0.43) | POLBKMT2AALDH1A1CA4CA1 | |
| SCHEMBL17897623 | 0.79 | NR1H2 (0.59) | S100A4POLBNR1H2NR1H3NPC1 | |
| SCHEMBL12710425 | 0.75 | LMNA (0.47) | POLBKMT2AALDH1A1CA4CA1 | |
| SCHEMBL14016924 | 0.75 | CA9 (0.64) | POLBKMT2AALDH1A1CA4CA1 | |
| SCHEMBL31085044 | 0.75 | S100A4 (0.53) | S100A4POLBNR1H2NR1H3NPC1 | |
| SCHEMBL10046076 | 0.75 | POLB (0.76) | S100A4POLBRAB9AKMT2AALDH1A1 | |
| SCHEMBL10947293 | 0.74 | S100A4 (0.71) | S100A4NPC1MAPTRAB9AKMT2A | |
| SCHEMBL12710422 | 0.72 | LMNA (0.47) | POLBKMT2AALDH1A1CA4CA1 | |
| SCHEMBL12710973 | 0.72 | ALDH1A1 (0.42) | POLBMAPTKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667046-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7423155-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080145907-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-7361767-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-04-22 | — | — | US | disclosed |
| US-7351838-B2 | N-sulfonyldicarboximide containing tethering compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070154937-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145907-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | NAPA, MSN, NSFL1C | S100A4 1389/4885POLB 4861/4885NR1H2 4763/4885 |
| US-20070154937-A1 | N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS | NAPA, MSN, NSFL1C | S100A4 1389/4885POLB 4861/4885NR1H2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.